Men with Low-Risk Prostate Cancer Face Lower All-Cause Mortality vs. Cancer-Free Men

Share this content:

the Cancer Therapy Advisor take:

Men with low-risk prostate cancer (PCa) face lower all-cause mortality compared to PCa-free men due to lower cardiovascular mortality.

Additionally, men with intermediate or high risk face substantial death risk regardless of Charlson comorbidity index (CCI).

These results were part of a recent study published in BJU International which looked at patient data gathered from PCBase Sweden. Mieke van Hemelrijck, PHD, and fellow researchers at King’s College London in the UK observed 57,187 men diagnosed with localized PCa between 1997 to 2009 as well as 114,374 age- and county-matched PCa-free control men.

They found that in men with low-risk PCa, all-cause mortality after 10 years was 18 percent compared to corresponding men without PCa who were at 21 percent, with 31 percent of patients dying from CVD compared to 37 percent, respectively.

In low-risk men, PCa was the third most common cause of death after cardiovascular disease and other cancers. In men with intermediate and high-risk localized PCa, their disease was the most common cause of death.

Neal D. Shore, MD, FACS, sits down to discuss PROSTVAC targeted immunotherapy for prostate cancer.
Men with low-risk PCa face lower all-cause mortality compared to PCa-free men.
In this study, authors want to detail the distribution of causes of death for localised prostate cancer (PCa). Men with low-risk PCa had lower all-cause mortality than PCa-free men due to lower cardiovascular mortality, driven by early detection selection.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters